What is the clinical impact of cerebrospinal fluid biomarkers on final diagnosis and management in patients with mild cognitive impairment in clinical practice? Results from a nation-wide prospective survey in France

OBJECTIVES: New diagnostic criteria for Alzheimer’s disease (AD) include cerebrospinal fluid (CSF) biomarkers that allow diagnosis at the stage of mild cognitive impairment (MCI). However, the impact of CSF biomarkers in MCI populations in clinical practice has been poorly evaluated. The objective o...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:BMJ Open
Hlavní autoři: Cognat, Emmanuel, Mouton Liger, François, Troussière, Anne-Cécile, Wallon, David, Dumurgier, Julien, Magnin, Eloi, Duron, Emmanuelle, Gabelle, Audrey, Croisile, Bernard, de la Sayette, Vincent, Jager, Alain, Blanc, Frederic, Bouaziz-Amar, Elodie, Miguet-Alfonsi, Carole, Quillard, Muriel, Schraen, Susanna, Philippi, Nathalie, Beaufils, Emilie, Pasquier, Florence, Hannequin, Didier, Robert, Philippe, Hugon, Jacques, Paquet, Claire
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Publishing Group 2019
Témata:
Neurology
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6549619/
https://ncbi.nlm.nih.gov/pubmed/31152032
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2018-026380
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky